BCM
NRIX icon

Boxer Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Boxer Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Hold
100,000
– – 0.18% 55
2026
Q1 		$1.55M Hold
100,000
– – 0.2% 48
2025
Q4 		$1.9M Sell
100,000
-75,000
-43% -$1.08M 0.42% 36
2025
Q3 		$1.62M Hold
175,000
– – 0.52% 26
2025
Q2 		$1.99M Sell
175,000
-388,067
-69% -$4.19M 1% 15
2025
Q1 		$6.69M Hold
563,067
– – 2.01% 18
2024
Q4 		$10.6M Buy
+563,067
New +$12.9M 0.9% 31

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Boxer Capital Management's NRIX Position: Q2 2026 in Review

Boxer Capital Management held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 100,000 shares worth $2.43M. The position accounts for 0.18% of the portfolio, ranked #55.

Boxer Capital Management first reported a position in NRIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.6M in Q4 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Boxer Capital Management held 100,000 shares of Nurix Therapeutics worth $2.43M as of Q2 2026.
  • Boxer Capital Management left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up 0.18% of Boxer Capital Management's portfolio in Q2 2026, its #55 holding.
  • Boxer Capital Management first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Boxer Capital Management's Nurix Therapeutics position peaked at $10.6M in Q4 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.